MLAB Quote, Financials, Valuation and Earnings

CPS Technologies has a net margin of 5.93% compared to Mesa Laboratories's net margin of -24.55%. Mesa Laboratories's return on equity of -98.4% beat CPS Technologies's return on equity of -11.95%.

Mesa Laboratories has a consensus price target of $133.33, signalling downside risk potential of -7.53%. On the other hand CPS Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesa Laboratories has higher upside potential than CPS Technologies, analysts believe Mesa Laboratories is more attractive than CPS Technologies.

Mesa Laboratories has a beta of 0.820, which suggesting that the stock is 18.046% less volatile than S&P 500. In comparison CPS Technologies has a beta of 1.220, suggesting its more volatile than the S&P 500 by 21.997%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.44%. CPS Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. CPS Technologies pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $57.8M, which are larger than CPS Technologies quarterly revenues of $4.2M. Mesa Laboratories's net income of $3.4M is higher than CPS Technologies's net income of -$1M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while CPS Technologies's PE ratio is 35.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 3.42x versus 1.20x for CPS Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Focus Universal has a net margin of 5.93% compared to Mesa Laboratories's net margin of -6910.88%. Mesa Laboratories's return on equity of -98.4% beat Focus Universal's return on equity of -82.24%.

Mesa Laboratories has a consensus price target of $133.33, signalling downside risk potential of -7.53%. On the other hand Focus Universal has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesa Laboratories has higher upside potential than Focus Universal, analysts believe Mesa Laboratories is more attractive than Focus Universal.

Mesa Laboratories has a beta of 0.820, which suggesting that the stock is 18.046% less volatile than S&P 500. In comparison Focus Universal has a beta of -0.316, suggesting its less volatile than the S&P 500 by 131.617%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.44%. Focus Universal offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Focus Universal pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $57.8M, which are larger than Focus Universal quarterly revenues of $74.2K. Mesa Laboratories's net income of $3.4M is higher than Focus Universal's net income of $1.4M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Focus Universal's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 3.42x versus 56.09x for Focus Universal. Usually stocks with elevated PS ratios are considered overvalued.

Qorvo has a net margin of 5.93% compared to Mesa Laboratories's net margin of -1.67%. Mesa Laboratories's return on equity of -98.4% beat Qorvo's return on equity of -3.94%.

Mesa Laboratories has a consensus price target of $133.33, signalling downside risk potential of -7.53%. On the other hand Qorvo has an analysts' consensus of $93.23 which suggests that it could grow by 29.24%. Given that Qorvo has higher upside potential than Mesa Laboratories, analysts believe Qorvo is more attractive than Mesa Laboratories.

Mesa Laboratories has a beta of 0.820, which suggesting that the stock is 18.046% less volatile than S&P 500. In comparison Qorvo has a beta of 1.399, suggesting its more volatile than the S&P 500 by 39.874%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.44%. Qorvo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Qorvo pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $57.8M, which are smaller than Qorvo quarterly revenues of $1B. Mesa Laboratories's net income of $3.4M is higher than Qorvo's net income of -$17.4M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Qorvo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 3.42x versus 1.76x for Qorvo. Usually stocks with elevated PS ratios are considered overvalued.

Sono-Tek has a net margin of 5.93% compared to Mesa Laboratories's net margin of 6.6%. Mesa Laboratories's return on equity of -98.4% beat Sono-Tek's return on equity of 9.33%.

Mesa Laboratories has a consensus price target of $133.33, signalling downside risk potential of -7.53%. On the other hand Sono-Tek has an analysts' consensus of -- which suggests that it could grow by 123.84%. Given that Sono-Tek has higher upside potential than Mesa Laboratories, analysts believe Sono-Tek is more attractive than Mesa Laboratories.

Mesa Laboratories has a beta of 0.820, which suggesting that the stock is 18.046% less volatile than S&P 500. In comparison Sono-Tek has a beta of -0.197, suggesting its less volatile than the S&P 500 by 119.669%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.44%. Sono-Tek offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Sono-Tek pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $57.8M, which are larger than Sono-Tek quarterly revenues of $5.2M. Mesa Laboratories's net income of $3.4M is higher than Sono-Tek's net income of $340.7K. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Sono-Tek's PE ratio is 47.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 3.42x versus 3.28x for Sono-Tek. Usually stocks with elevated PS ratios are considered overvalued.